



20 March 2020
EMA/141885/2020
Media and Public Relations

Press release

Guidance to sponsors on how to manage clinical trials during the COVID-19 pandemic

The European Commission, the European Medicines Agency (EMA) and national Head of Medicines Agencies (HMA) have published [new](#) recommendations for sponsors on how to manage the conduct of clinical trials in the context of the coronavirus disease (COVID-19) pandemic. The impact of the pandemic on European health systems and more broadly on society, will make it necessary for sponsors to adjust how they manage clinical trials and the people who participate in these trials.

The guidance provides concrete information on changes and protocol deviations which may be needed in the conduct of clinical trials to deal with extraordinary situations, e.g. if trial participants need to be in self-isolation or quarantine, access to public places (including hospitals) is limited due to the risk of spreading infections, and healthcare professionals are being reallocated.

This guidance includes a harmonised set of recommendations, to ensure the utmost safety of trial participants across the European Union while preserving the quality of the data generated by the trials. It also advises how these changes should be communicated to authorities.

There is specific advice on the initiation of new clinical trials for treatments of COVID-19, and in particular on the need for large, multinational trial protocols. This is in line with the [call issued on Thursday](#) by EMA's human medicines committee (CHMP) for robust trial methodology in clinical trials for potential COVID-19 treatments or vaccines.

The guidance was agreed by the Clinical Trials Expert Group (CTEG) of the European Commission supported by EMA, the Clinical Trials Facilitation and Coordination Group (CTFG) of HMA and the GCP Inspectors' Working Group. It provides a harmonised approach in the conduct of trials, in order to mitigate the negative effects of the pandemic.

In the EU, clinical trials are authorised and supervised at national level. Sponsors are advised to also check whether there might be specific national legislation and guidance in place to complement or in some cases to take priority over this new guidance.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



Notes

1. The guidance on the management of clinical trials during COVID-19 is published on the [European Commission's website](#).
2. For more information on the EU's response on coronavirus 2019-nCoV, see European Commission: [Coronavirus response](#).
3. More information about EMA's response to COVID-19 is available [here](#).
4. More information about the CTFG is available [here](#).
5. Information on the GCP Inspector's working group is available [here](#).
6. Information on the CTEG (Clinical Trials Expert Group) is available [here](#).

Contact our press officers

EMA press office

Tel. +31 (0)88 781 8427

E-mail: press@ema.europa.eu

European Commission

Stefan de Keersmaecker, Spokesperson public health and food safety

E-mail: E-mail: Stefan.DE-KEERSMAECKER@ec.europa.eu

Darragh Cassidy, press officer

E-mail: darragh.cassidy@ec.europa.eu

Heads of Medicines Agencies Permanent Secretariat

c/o Paul-Ehrlich-Institute

Paul-Ehrlich-Straße 51-59

63225 Langen

Germany

E-mail: hma-ps@pei.de